December 3-5, 2019

Northeastern University Biopharmaceutical Analysis Training Laboratory

Northeastern University Biopharmaceutical Analysis Training Laboratory


Northeastern University is home to the Asia-Pacific Economic Cooperation (APEC) Center of Excellence in Biotherapeutics.

Research in biotherapeutics is providing promising and innovative drugs that provide hope to millions of patients around the world. Yet these same drugs may pose risks if the challenges inherent in their production, distribution, and marketing are not properly understood and regulated.

New technologies are emerging that enable scientists and regulators to better analyze and characterize biotherapeutics. Industry, government regulators, and authorized health professionals need to be trained on these new technologies to maximize their potential, as well as minimize the risk of potential misuse or contamination. This training should involve theoretical science, clinical science, and physical hands-on skills.


Welcome to the Northeastern APEC LSIF RHSC Center of Excellence in Biotherapeutics. Northeastern University, along with the APEC Regulatory Harmonization Steering Committee, are committed to promoting regulatory convergence for Biologics across the Asia-Pacific region, and the globe.  We are able to promote regulatory convergence through online learning, case studies, and providing experiential, hands-on, training to participants.  Through these learning experiences, participants are able to network with their colleagues from other agencies across the globe, as well as, with the Center’s faculty.  Through regulatory convergence, safe and effective drugs will be brought to market faster, thus benefiting patients.  Through all the activities performed at the Center, the patient is always the central focus.       

Jared Auclair, PhD
Director of Biotechnology Professional Science Masters and Training
Chemistry and Chemical Biology
Northeastern University



BATL strives to enable workforce training alongside global medical regulatory convergence in an effort to assist in accelerated drug approvals and ultimate drug access for patients.


Our diverse, innovative, and globally-recognized experiential learning and credentialing programs offer a neutral platform to train the industry’s workforce while also converging the intricacies of global regulatory considerations for pharmaceutical and biopharmaceutical products.  In doing so, we increase the potential of accelerated drug approvals with quality, safety and efficacy at the forefront, thus impacting patients for improved access to medicines worldwide.